INSIGHT Partner Profile: Tampere University
•
0 likes•63 views
We present you a part of our Tampere University's team - FHAIVE! Besides producing excellent science, they are in charge or coordinating this project as well Tampere University, Faculty of Medicine and Health Technology.
Report
Share
Report
Share
Download to read offline
Recommended
PTSM 2.pptx
Toxicokinetics deals with absorption , distribution , biotransformation and excretion of chemicals .
According to ICH S3A guidance on the assessment of systemic exposure in toxicity studies , toxicokinetics is defined as the generation of pharmacokinetics data , either as an integral component in the conduct of non-clinical toxicity studies or in specially designed supportive studies , in order to assess systemic exposure.
Toxicokinetics is the science to understand what the body does with a drug when the drug is given at a relatively high dose . Toxicokinetics play a major role in interpreting the histopathological finding in a toxicological study.
Toxicokinetic is essentially the study of "how a substance gets into the body and what happens to it in the body."
The primary objective of toxicokinetic is:
• To describe the systemic exposure achieved in animals and its relationship to dose level and the time course of the toxicity study.
Secondary objectives are:
• To relate the exposure achieved in toxicity studies to toxicological findings and
contribute to the assessment of the relevance of these findings to clinical safety.
• To support the choice of species and treatment regimen in non-clinical toxicity studies.
• To provide information which, in conjunction with the toxicity findings, contributes to the design of subsequent non-clinical toxicity studies.
The primary purpose of toxicokinetic studies is to determine the rate, extent and duration of systemic exposure of the test animal species to the test compound at the different dose levels employed during toxicity studies and to provide data for direct comparison with human exposure to the test compound.
These data help to understand the relationship between observed toxicity and administered dose. They also play a role in the clinical setting, assisting in the setting of plasma limits for early human exposure and in the calculation of safety margins.
A major challenge in the risk/benefit assessment of new chemical entities is the rational and reliable extrapolation of preclinical (nonclinical) safety evaluation data from animals to humans.
Toxicity studies, core to the safety evaluation process, are designed to determine a no observed toxic effect level as well as an observed toxic effect level.
Traditionally, these levels have been those of administered dose, and safety margins are derived as the ratio between the preclinical no observed toxic effect dose level in animals and the clinical (or environmental) dose level in humans.
In reality, however, safety margins thus derived are often optimistic guesses because they do not take into account the respective systemic exposures to the test compound during the preclinical studies and eventual human clinical (or environmental) use.
Toxicokinetics involves the generation of kinetic data to assess systemic exposure, either as an integral component of preclinical toxicity studies, or in specially designed supportive studies.
Biochemistry Career Progression
This document discusses evaluating the effectiveness of public service announcements (PSAs) that use celebrity endorsements. It proposes researching whether celebrity endorsements increase the effectiveness of PSAs by measuring audience recall and behavioral change. The research methodology would involve a between-subjects experiment where participants are randomly assigned to view either a PSA with a celebrity endorser or one without. Effectiveness would be assessed by comparing audience recall and willingness to change behavior between the two groups.
Pharmacophore modeling: A continuously evolving tool for computational drug d...
In the latest two or three years progressive
applications of pharmacophore modeling continue to appear in literature. Pharmacophore based parallel screening, for instance, has been introduced in 2006. Moreover, in 2008, a survey discussing the prospective impact of virtual screening techniques in the
discovery of bioactive natural products has been published.
TWhite CV_Aclairo_Jan 2016
Tacey E.K. White has over 25 years of experience in pharmaceutical safety assessment and drug development. She currently works as a senior consultant, advising on nonclinical safety strategies throughout drug development. Previously, she held roles at Exponent, Covance, and GlaxoSmithKline, where she designed and directed developmental and reproductive toxicity and juvenile toxicity studies to support regulatory submissions. She has deep expertise in areas like developmental toxicity, juvenile toxicity, and pregnancy and lactation labeling.
Toxicological risk assessment of chemicals
This document presents an overview of toxicological risk assessment of chemicals. It discusses the key international and federal bodies involved in chemical risk assessment like WHO, EPA, and OECD. The risk assessment process involves five steps - hazard identification, hazard evaluation/dose-response assessment, exposure assessment, and risk characterization. Various factors in risk perception and comparative analyses of risk are also reviewed. The goal of risk assessment is to balance risks and benefits of chemicals and set safety limits to protect public health.
ECOPHARMACOLOGY.pptx
ECOPHARMACOLOGY - SAFE DISPOSAL OF DRUGS SO AS NOT TO CAUSE ECOLOGICAL DAMAGE DUE TO PHARMACEUTICAL EFFLUENTS.
Lior - Bracco Radiology Symposia Booklet
This document provides an agenda and materials for a symposium titled "Improving Medication Safety in the Radiology Setting". The agenda includes presentations on medication administration systems and medications used in radiology, medication safety issues and strategies in radiology, and regulatory and accreditation requirements related to medication use in radiology. The objectives are to describe how medications are handled in radiology, explain new FDA classifications for contrast, identify medication errors in radiology, discuss safety strategies, and describe regulatory standards. Faculty include experts from the Institute for Safe Medication Practices who will discuss actual error cases and risk reduction.
INTERPROFESSIONAL COLLABORATION IN PHARMACOEPIDEMIOLOGY STUDIES
Interprofessional collaboration occurs when two or more professions work together to achieve common goals. It allows participants to accomplish more together than individually and serve larger groups of people. Pharmacoepidemiology applies epidemiological methods to study drug use and effects in populations. Observational studies like cohort and case-control studies are commonly used. Randomized clinical trials can also be used. Pharmacoepidemiology helps quantify adverse drug reactions, identify rare side effects, and improve safe and effective drug use. Interprofessional collaboration is important for conducting pharmacoepidemiology research.
Recommended
PTSM 2.pptx
Toxicokinetics deals with absorption , distribution , biotransformation and excretion of chemicals .
According to ICH S3A guidance on the assessment of systemic exposure in toxicity studies , toxicokinetics is defined as the generation of pharmacokinetics data , either as an integral component in the conduct of non-clinical toxicity studies or in specially designed supportive studies , in order to assess systemic exposure.
Toxicokinetics is the science to understand what the body does with a drug when the drug is given at a relatively high dose . Toxicokinetics play a major role in interpreting the histopathological finding in a toxicological study.
Toxicokinetic is essentially the study of "how a substance gets into the body and what happens to it in the body."
The primary objective of toxicokinetic is:
• To describe the systemic exposure achieved in animals and its relationship to dose level and the time course of the toxicity study.
Secondary objectives are:
• To relate the exposure achieved in toxicity studies to toxicological findings and
contribute to the assessment of the relevance of these findings to clinical safety.
• To support the choice of species and treatment regimen in non-clinical toxicity studies.
• To provide information which, in conjunction with the toxicity findings, contributes to the design of subsequent non-clinical toxicity studies.
The primary purpose of toxicokinetic studies is to determine the rate, extent and duration of systemic exposure of the test animal species to the test compound at the different dose levels employed during toxicity studies and to provide data for direct comparison with human exposure to the test compound.
These data help to understand the relationship between observed toxicity and administered dose. They also play a role in the clinical setting, assisting in the setting of plasma limits for early human exposure and in the calculation of safety margins.
A major challenge in the risk/benefit assessment of new chemical entities is the rational and reliable extrapolation of preclinical (nonclinical) safety evaluation data from animals to humans.
Toxicity studies, core to the safety evaluation process, are designed to determine a no observed toxic effect level as well as an observed toxic effect level.
Traditionally, these levels have been those of administered dose, and safety margins are derived as the ratio between the preclinical no observed toxic effect dose level in animals and the clinical (or environmental) dose level in humans.
In reality, however, safety margins thus derived are often optimistic guesses because they do not take into account the respective systemic exposures to the test compound during the preclinical studies and eventual human clinical (or environmental) use.
Toxicokinetics involves the generation of kinetic data to assess systemic exposure, either as an integral component of preclinical toxicity studies, or in specially designed supportive studies.
Biochemistry Career Progression
This document discusses evaluating the effectiveness of public service announcements (PSAs) that use celebrity endorsements. It proposes researching whether celebrity endorsements increase the effectiveness of PSAs by measuring audience recall and behavioral change. The research methodology would involve a between-subjects experiment where participants are randomly assigned to view either a PSA with a celebrity endorser or one without. Effectiveness would be assessed by comparing audience recall and willingness to change behavior between the two groups.
Pharmacophore modeling: A continuously evolving tool for computational drug d...
In the latest two or three years progressive
applications of pharmacophore modeling continue to appear in literature. Pharmacophore based parallel screening, for instance, has been introduced in 2006. Moreover, in 2008, a survey discussing the prospective impact of virtual screening techniques in the
discovery of bioactive natural products has been published.
TWhite CV_Aclairo_Jan 2016
Tacey E.K. White has over 25 years of experience in pharmaceutical safety assessment and drug development. She currently works as a senior consultant, advising on nonclinical safety strategies throughout drug development. Previously, she held roles at Exponent, Covance, and GlaxoSmithKline, where she designed and directed developmental and reproductive toxicity and juvenile toxicity studies to support regulatory submissions. She has deep expertise in areas like developmental toxicity, juvenile toxicity, and pregnancy and lactation labeling.
Toxicological risk assessment of chemicals
This document presents an overview of toxicological risk assessment of chemicals. It discusses the key international and federal bodies involved in chemical risk assessment like WHO, EPA, and OECD. The risk assessment process involves five steps - hazard identification, hazard evaluation/dose-response assessment, exposure assessment, and risk characterization. Various factors in risk perception and comparative analyses of risk are also reviewed. The goal of risk assessment is to balance risks and benefits of chemicals and set safety limits to protect public health.
ECOPHARMACOLOGY.pptx
ECOPHARMACOLOGY - SAFE DISPOSAL OF DRUGS SO AS NOT TO CAUSE ECOLOGICAL DAMAGE DUE TO PHARMACEUTICAL EFFLUENTS.
Lior - Bracco Radiology Symposia Booklet
This document provides an agenda and materials for a symposium titled "Improving Medication Safety in the Radiology Setting". The agenda includes presentations on medication administration systems and medications used in radiology, medication safety issues and strategies in radiology, and regulatory and accreditation requirements related to medication use in radiology. The objectives are to describe how medications are handled in radiology, explain new FDA classifications for contrast, identify medication errors in radiology, discuss safety strategies, and describe regulatory standards. Faculty include experts from the Institute for Safe Medication Practices who will discuss actual error cases and risk reduction.
INTERPROFESSIONAL COLLABORATION IN PHARMACOEPIDEMIOLOGY STUDIES
Interprofessional collaboration occurs when two or more professions work together to achieve common goals. It allows participants to accomplish more together than individually and serve larger groups of people. Pharmacoepidemiology applies epidemiological methods to study drug use and effects in populations. Observational studies like cohort and case-control studies are commonly used. Randomized clinical trials can also be used. Pharmacoepidemiology helps quantify adverse drug reactions, identify rare side effects, and improve safe and effective drug use. Interprofessional collaboration is important for conducting pharmacoepidemiology research.
Decision Aids 2017
Decision aids help patients and clinicians decide on the best course of treatment, incorporating evidence from systematic reviews, patient values, individual risk factors, and expert recommendations, all in an intuitive and interactive format.
Toxicology types and definition.pptx
This document provides an overview of toxicology and its various branches. It defines key terms like toxicants, toxicity, acute toxicity, chronic toxicity, dose, etc. It describes the different types of toxicology like general toxicology, mechanistic toxicology, descriptive toxicology, and regulatory toxicology. For each type, it provides examples and explains their purpose and importance. It also discusses the importance of guidelines in regulatory toxicity studies for ensuring safety, efficacy and quality of medicines.
Different types of toxicity studies_131223.pdf
This presentation provides insight about different toxicity studies
Role of a Pharmacologist By Dr.Harmanjit Singh
A pharmacologist has several key roles:
1. Medical education - Teaching undergraduate and postgraduate students about rational drug use, effects, toxicity, and interactions.
2. Research - Conducting both basic and clinical research, ensuring adherence to guidelines for clinical trials and ethical reviews.
3. Regulatory affairs - Involved in essential drug lists, national drug policy, and regulatory bodies like drug authorities.
Jms V47 I4 Special Feature (1)
The document describes a new software tool called GenoMass that can analyze tandem mass spectrometry sequencing data of oligonucleotides to identify the exact location of potential adducts. GenoMass was developed by researchers at Northeastern University led by Professor Paul Vouros. The analysis of DNA adducts is important for understanding DNA damage and related diseases. The article also provides biographies of the authors and researchers involved in developing GenoMass.
Resume_Frederic_Feru_october_2015
This document summarizes the qualifications of Frederic Feru, an experienced medicinal chemist. Over his 30 year career, Feru has worked at several pharmaceutical companies and research institutions. He has expertise in medicinal chemistry, drug design, organic synthesis, and leading projects from hit identification to clinical trials. Some of Feru's accomplishments include advancing a PDE4 inhibitor into first-in-human trials, progressing 5 projects to in vivo proof of concept, and helping to develop a FAAH inhibitor that reached Phase II clinical trials.
PHINDaccess Conference Omics Challenges in Infectious Diseases Research - K...
PHINDaccess Conference
Omics Challenges in Infectious Diseases Research
- Kick off meeting - November 5, 2018
Preprint book the management strategy in toxicology and poisoning luisetto m...
Preprint book the management strategy in toxicology and poisoning luisetto m...M. Luisetto Pharm.D.Spec. Pharmacology
This document discusses the importance of management strategies in toxicology and poisoning situations. It emphasizes the need for rapid and effective emergency procedures, communication systems, qualified clinical staff, documentation, and information sharing to properly treat patients. Adequate management is crucial to efficiently control complex poisoning processes and achieve good clinical and economic outcomes. The document recommends applying various managerial techniques from industries like healthcare, disaster planning, and project management to help optimize the treatment of toxicological events.2013 ets ce course materials (stresa italy)
This document summarizes an education course on testing strategies for biopharmaceuticals. The course included three speakers and covered the following topics:
1. Manon Beekhuijzen from WIL Research Europe gave an introduction to biopharmaceuticals and developmental and reproductive toxicity (DART) testing. She discussed the traditional segmented approach to DART testing and considerations for biopharmaceuticals from ICH S5 and S6 guidelines.
2. Paul Barrow from Roche discussed the non-clinical testing of vaccines, focusing on the FDA 2006 guidance for vaccines intended for use during pregnancy.
3. Gary Chellman from Charles River Laboratories spoke about the use of nonhuman primates for biopharmaceutical
CV of Dr.Qinghua Wu
Dr. Qing-Hua Wu is a lecturer at Yangtze University who received his Ph.D. in Veterinary Pharmacology and Toxicology from Huazhong Agricultural University in 2013. His research focuses on the metabolism, toxicity, and signal transduction pathways of mycotoxins such as trichothecenes. Specifically, he investigates the functional crosstalk of MAPK and JAK/STAT signaling pathways induced by trichothecenes and the regulation of cell apoptosis. He has also studied the biotransformation of T-2 toxin in various food-producing animals and the degradation of deoxynivalenol during extrusion cooking processes. Dr. Wu has published over 30
CV of Dr.Qinghua Wu
Dr. Qing-Hua Wu is a lecturer at Yangtze University who received his Ph.D. in Veterinary Pharmacology and Toxicology from Huazhong Agricultural University in 2013. His research focuses on the metabolism, toxicity, and signal transduction pathways of mycotoxins such as trichothecenes. Specifically, he investigates the functional crosstalk of MAPK and JAK/STAT signaling pathways induced by trichothecenes and the regulation of cell apoptosis. He has also studied the biotransformation of T-2 toxin in various food-producing animals and the degradation of deoxynivalenol during extrusion cooking processes. Dr. Wu has published over 30
cover letter UPMC
This document is a cover letter from Katherine Nicholas, a PhD candidate in Biostatistics at the Medical University of South Carolina, defending her dissertation on March 21, 2016 about covariate adjustment in non-inferiority clinical trials. Her work addresses how failing to adjust for important prognostic factors can impact type I error, and she has developed new methodology for choosing covariates. She has had enriching research experiences serving as a statistical analyst and collaborating on multicenter clinical trials. She is seeking a position where she can be an independent researcher, cultivate new collaborations, and mentor others.
Lecture_3-_Branches___Scope_of_Toxicology.pptx
Toxicology has many branches that study the harmful effects of various agents on living organisms. The main branches include clinical toxicology, which deals with the effects of poisons on humans and animals and their treatment; environmental toxicology, which studies the effects of chemicals, biological and physical agents on populations and ecosystems; and forensic toxicology, which applies toxicology to legal investigations of death, poisoning, and drug use. The scope of toxicology includes understanding mechanisms of toxic agents, recognizing health hazards, developing safety standards, and identifying treatments for exposures.
lecture 2 (1).pptx
This document provides an overview of the scope and education of pharmacy. It discusses the vision and mission of improving human health through innovation in education, research, and applied practices. It then outlines the key departments in a pharmacy faculty, including biochemistry, pharmacognosy, pharmacology, clinical pharmacy, pharmaceutical chemistry, pharmaceutics, microbiology, and analytical chemistry. It also discusses the roles of these departments and topics covered, such as the structure and functions of biomolecules, herbal medicines, mechanisms of drug action, drug therapy selection, and development of new drug entities. Postgraduate programs including Masters, PhD, and diplomas in various specialty areas are also mentioned.
Resume - Palur Gunasekar
This CV summarizes the qualifications of Palur G. Gunasekar, who has over 25 years of experience in research biology and toxicology. He has expertise in various areas including neurotoxicology, reproductive toxicity, inhalation toxicology, and traumatic brain injury research. Some of his accomplishments include authoring numerous publications, obtaining competitive grants from NIH and DOD, and excelling in management and leadership roles at various academic and government institutions.
KristenLBeuving-Word CV(05-15)
Kristen Beuving has over 15 years of experience in research including analytical chemistry, toxicology, behavioral pharmacology, and microscopy. She has held roles such as executive assistant, weekend group leader, associate study director, research analyst, and research assistant. Beuving has extensive knowledge of FDA and regulatory guidelines and experience managing projects, personnel, and laboratory operations. She has strong leadership, problem solving, and technical skills.
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Running head NURSING PROBLEM .docx
Running head: NURSING PROBLEM 1
NURSING PROBLEM 2
Nursing Problem
Student’s Name
Institutional Affiliation
Date
Specialization: Nursing Practitioner.
As a nursing practitioner, the major roles include the assessment of the needs of the patients. A nursing practitioner also orders and interprets test from laboratories, they do illness and disease diagnosis, medication prescription and formulate plans for treatment. There are a number of challenges that face the nurse in their field of practices. This paper will focus to discuss the hazards in the workspace of these practitioners. It will also seek to find a way of solving these challenge using innovative means.
The Problem of Interest
Hazard in The Nursing Field.
The nursing field of practice is one of the most dangerous places of working as one does work in a delicate environment where one is in the risks of being infected or even injuring oneself. Nurses are faced with a number of risks in daily job activities. Some of these hazards include injuries, flu germs, hand washing –related dermatitis and pathogens that are based in the blood among others.
According to the report produced by OSHA, about 5.6 million of 12.2 million workers are under the risk of being exposed to blood borne pathogens. This is a big number of health workers under the risk meaning that soon there will be a shortage of health nursing or health workers in general. Moreover, the rates of risks are higher in the health care industry than any other industries. This industry has registered around 35000 injuries covering different parts of the body. These range from the shoulders, hands, feet, and back. These statistics are according to the Bureau Labor Statistics (Gooch, 2015).
Apart from the acute injuries discussed, they also suffer harm exposed on their hands. From a recent study carried out in the University of Manchester, the health workers that follow protocols are 4.5 times exposed to skin damage risks. The report also reported up to 25 percent of cases of irritant contact dermatitis.
These individuals also get exposed to infectious diseases in their areas of practice. One of the most commonly contacted infection is Hepatitis B (HBV). This is infection can be contacted via blood contact, feces, saliva, and semen. This instrument of spreading the infection is in contact with the patient and also the needles (Gooch, 2015). Nursing practitioners also risk exposure to toxic substances in the clinical environment. Radiation is another risk that comes majorly from the ionizing radiation. Complications associated with radiation include skin cancer, leukemia, and cancer among others. One comes to contact with this radiation in the instances of performing x-ray scans. Another challenge that faces nursing.
20240610_INSIGHT_PartnerProfile-02_Tampere.pdf
Continuing with the partner Introduction, Tampere University has another group operating at the INSIGHT project! Meet members of the Industrial Engineering and Management Unit - Aki, Jaakko, Olga, and Vilma!
20231019to20_OIP-2023_SFriedrichs.pdf
Presentation by Dr Steffi Friedrichs, entitled: Nanotechnology at the Crossroads of Converging Technologies: Unveiling the Future of Innovation
presented at the meeting on 'Open Innovation for Materials Modelling, Design and Manufacturing', 19th – 20th October 2023, at the Luxembourg Institute of Science & Technology.
More Related Content
Similar to INSIGHT Partner Profile: Tampere University
Decision Aids 2017
Decision aids help patients and clinicians decide on the best course of treatment, incorporating evidence from systematic reviews, patient values, individual risk factors, and expert recommendations, all in an intuitive and interactive format.
Toxicology types and definition.pptx
This document provides an overview of toxicology and its various branches. It defines key terms like toxicants, toxicity, acute toxicity, chronic toxicity, dose, etc. It describes the different types of toxicology like general toxicology, mechanistic toxicology, descriptive toxicology, and regulatory toxicology. For each type, it provides examples and explains their purpose and importance. It also discusses the importance of guidelines in regulatory toxicity studies for ensuring safety, efficacy and quality of medicines.
Different types of toxicity studies_131223.pdf
This presentation provides insight about different toxicity studies
Role of a Pharmacologist By Dr.Harmanjit Singh
A pharmacologist has several key roles:
1. Medical education - Teaching undergraduate and postgraduate students about rational drug use, effects, toxicity, and interactions.
2. Research - Conducting both basic and clinical research, ensuring adherence to guidelines for clinical trials and ethical reviews.
3. Regulatory affairs - Involved in essential drug lists, national drug policy, and regulatory bodies like drug authorities.
Jms V47 I4 Special Feature (1)
The document describes a new software tool called GenoMass that can analyze tandem mass spectrometry sequencing data of oligonucleotides to identify the exact location of potential adducts. GenoMass was developed by researchers at Northeastern University led by Professor Paul Vouros. The analysis of DNA adducts is important for understanding DNA damage and related diseases. The article also provides biographies of the authors and researchers involved in developing GenoMass.
Resume_Frederic_Feru_october_2015
This document summarizes the qualifications of Frederic Feru, an experienced medicinal chemist. Over his 30 year career, Feru has worked at several pharmaceutical companies and research institutions. He has expertise in medicinal chemistry, drug design, organic synthesis, and leading projects from hit identification to clinical trials. Some of Feru's accomplishments include advancing a PDE4 inhibitor into first-in-human trials, progressing 5 projects to in vivo proof of concept, and helping to develop a FAAH inhibitor that reached Phase II clinical trials.
PHINDaccess Conference Omics Challenges in Infectious Diseases Research - K...
PHINDaccess Conference
Omics Challenges in Infectious Diseases Research
- Kick off meeting - November 5, 2018
Preprint book the management strategy in toxicology and poisoning luisetto m...
Preprint book the management strategy in toxicology and poisoning luisetto m...M. Luisetto Pharm.D.Spec. Pharmacology
This document discusses the importance of management strategies in toxicology and poisoning situations. It emphasizes the need for rapid and effective emergency procedures, communication systems, qualified clinical staff, documentation, and information sharing to properly treat patients. Adequate management is crucial to efficiently control complex poisoning processes and achieve good clinical and economic outcomes. The document recommends applying various managerial techniques from industries like healthcare, disaster planning, and project management to help optimize the treatment of toxicological events.2013 ets ce course materials (stresa italy)
This document summarizes an education course on testing strategies for biopharmaceuticals. The course included three speakers and covered the following topics:
1. Manon Beekhuijzen from WIL Research Europe gave an introduction to biopharmaceuticals and developmental and reproductive toxicity (DART) testing. She discussed the traditional segmented approach to DART testing and considerations for biopharmaceuticals from ICH S5 and S6 guidelines.
2. Paul Barrow from Roche discussed the non-clinical testing of vaccines, focusing on the FDA 2006 guidance for vaccines intended for use during pregnancy.
3. Gary Chellman from Charles River Laboratories spoke about the use of nonhuman primates for biopharmaceutical
CV of Dr.Qinghua Wu
Dr. Qing-Hua Wu is a lecturer at Yangtze University who received his Ph.D. in Veterinary Pharmacology and Toxicology from Huazhong Agricultural University in 2013. His research focuses on the metabolism, toxicity, and signal transduction pathways of mycotoxins such as trichothecenes. Specifically, he investigates the functional crosstalk of MAPK and JAK/STAT signaling pathways induced by trichothecenes and the regulation of cell apoptosis. He has also studied the biotransformation of T-2 toxin in various food-producing animals and the degradation of deoxynivalenol during extrusion cooking processes. Dr. Wu has published over 30
CV of Dr.Qinghua Wu
Dr. Qing-Hua Wu is a lecturer at Yangtze University who received his Ph.D. in Veterinary Pharmacology and Toxicology from Huazhong Agricultural University in 2013. His research focuses on the metabolism, toxicity, and signal transduction pathways of mycotoxins such as trichothecenes. Specifically, he investigates the functional crosstalk of MAPK and JAK/STAT signaling pathways induced by trichothecenes and the regulation of cell apoptosis. He has also studied the biotransformation of T-2 toxin in various food-producing animals and the degradation of deoxynivalenol during extrusion cooking processes. Dr. Wu has published over 30
cover letter UPMC
This document is a cover letter from Katherine Nicholas, a PhD candidate in Biostatistics at the Medical University of South Carolina, defending her dissertation on March 21, 2016 about covariate adjustment in non-inferiority clinical trials. Her work addresses how failing to adjust for important prognostic factors can impact type I error, and she has developed new methodology for choosing covariates. She has had enriching research experiences serving as a statistical analyst and collaborating on multicenter clinical trials. She is seeking a position where she can be an independent researcher, cultivate new collaborations, and mentor others.
Lecture_3-_Branches___Scope_of_Toxicology.pptx
Toxicology has many branches that study the harmful effects of various agents on living organisms. The main branches include clinical toxicology, which deals with the effects of poisons on humans and animals and their treatment; environmental toxicology, which studies the effects of chemicals, biological and physical agents on populations and ecosystems; and forensic toxicology, which applies toxicology to legal investigations of death, poisoning, and drug use. The scope of toxicology includes understanding mechanisms of toxic agents, recognizing health hazards, developing safety standards, and identifying treatments for exposures.
lecture 2 (1).pptx
This document provides an overview of the scope and education of pharmacy. It discusses the vision and mission of improving human health through innovation in education, research, and applied practices. It then outlines the key departments in a pharmacy faculty, including biochemistry, pharmacognosy, pharmacology, clinical pharmacy, pharmaceutical chemistry, pharmaceutics, microbiology, and analytical chemistry. It also discusses the roles of these departments and topics covered, such as the structure and functions of biomolecules, herbal medicines, mechanisms of drug action, drug therapy selection, and development of new drug entities. Postgraduate programs including Masters, PhD, and diplomas in various specialty areas are also mentioned.
Resume - Palur Gunasekar
This CV summarizes the qualifications of Palur G. Gunasekar, who has over 25 years of experience in research biology and toxicology. He has expertise in various areas including neurotoxicology, reproductive toxicity, inhalation toxicology, and traumatic brain injury research. Some of his accomplishments include authoring numerous publications, obtaining competitive grants from NIH and DOD, and excelling in management and leadership roles at various academic and government institutions.
KristenLBeuving-Word CV(05-15)
Kristen Beuving has over 15 years of experience in research including analytical chemistry, toxicology, behavioral pharmacology, and microscopy. She has held roles such as executive assistant, weekend group leader, associate study director, research analyst, and research assistant. Beuving has extensive knowledge of FDA and regulatory guidelines and experience managing projects, personnel, and laboratory operations. She has strong leadership, problem solving, and technical skills.
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Careers in epidemiology
Epidemiology is the study of the distribution and determinants of health-related states in populations. Traditional epidemiological studies use quantitative and qualitative designs, including observational and interventional methods. Candidates with degrees in fields like MBBS, nursing, pharmacy, statistics, nutrition, or other medical areas are eligible for epidemiology programs. As an epidemiologist, one may perform research, investigate disease outbreaks, and educate the public about health risks. Epidemiologists earn an average salary of Rs 240,000 per year in India. Notable institutes offering epidemiology programs include the University of Pune, Institute of Public Health Bangalore, National Institute of Epidemiology Chennai, and Achutha Menon Centre for Health
Running head NURSING PROBLEM .docx
Running head: NURSING PROBLEM 1
NURSING PROBLEM 2
Nursing Problem
Student’s Name
Institutional Affiliation
Date
Specialization: Nursing Practitioner.
As a nursing practitioner, the major roles include the assessment of the needs of the patients. A nursing practitioner also orders and interprets test from laboratories, they do illness and disease diagnosis, medication prescription and formulate plans for treatment. There are a number of challenges that face the nurse in their field of practices. This paper will focus to discuss the hazards in the workspace of these practitioners. It will also seek to find a way of solving these challenge using innovative means.
The Problem of Interest
Hazard in The Nursing Field.
The nursing field of practice is one of the most dangerous places of working as one does work in a delicate environment where one is in the risks of being infected or even injuring oneself. Nurses are faced with a number of risks in daily job activities. Some of these hazards include injuries, flu germs, hand washing –related dermatitis and pathogens that are based in the blood among others.
According to the report produced by OSHA, about 5.6 million of 12.2 million workers are under the risk of being exposed to blood borne pathogens. This is a big number of health workers under the risk meaning that soon there will be a shortage of health nursing or health workers in general. Moreover, the rates of risks are higher in the health care industry than any other industries. This industry has registered around 35000 injuries covering different parts of the body. These range from the shoulders, hands, feet, and back. These statistics are according to the Bureau Labor Statistics (Gooch, 2015).
Apart from the acute injuries discussed, they also suffer harm exposed on their hands. From a recent study carried out in the University of Manchester, the health workers that follow protocols are 4.5 times exposed to skin damage risks. The report also reported up to 25 percent of cases of irritant contact dermatitis.
These individuals also get exposed to infectious diseases in their areas of practice. One of the most commonly contacted infection is Hepatitis B (HBV). This is infection can be contacted via blood contact, feces, saliva, and semen. This instrument of spreading the infection is in contact with the patient and also the needles (Gooch, 2015). Nursing practitioners also risk exposure to toxic substances in the clinical environment. Radiation is another risk that comes majorly from the ionizing radiation. Complications associated with radiation include skin cancer, leukemia, and cancer among others. One comes to contact with this radiation in the instances of performing x-ray scans. Another challenge that faces nursing.
Similar to INSIGHT Partner Profile: Tampere University (20)
PHINDaccess Conference Omics Challenges in Infectious Diseases Research - K...
PHINDaccess Conference Omics Challenges in Infectious Diseases Research - K...
Preprint book the management strategy in toxicology and poisoning luisetto m...
Preprint book the management strategy in toxicology and poisoning luisetto m...
More from Steffi Friedrichs
20240610_INSIGHT_PartnerProfile-02_Tampere.pdf
Continuing with the partner Introduction, Tampere University has another group operating at the INSIGHT project! Meet members of the Industrial Engineering and Management Unit - Aki, Jaakko, Olga, and Vilma!
20231019to20_OIP-2023_SFriedrichs.pdf
Presentation by Dr Steffi Friedrichs, entitled: Nanotechnology at the Crossroads of Converging Technologies: Unveiling the Future of Innovation
presented at the meeting on 'Open Innovation for Materials Modelling, Design and Manufacturing', 19th – 20th October 2023, at the Luxembourg Institute of Science & Technology.
MACRAMÉ Contribution to the 'Standardisation Workshop & Panel Discussion' at ...
Dr Steffi Friedrichs of AcumenIST SRL participated in the ‘Standardisation Workshop & Panel Discussion’ at Graphene Week 2023, held from the 4th – 8th September 2023 in Gothenburg.
She contributed an introduction to the MACRAMÉ Project (Advanced Characterisation Methodologies to assess and predict the Health and Environmental Risks of Advanced Materials) and illustrated, how the nanotechnology community kicked off standardisation and harmonisation activities throughout 2005 to 2007, thereby laying the foundations for an extended, materials-specific approach to the collaborative development of standards (through ISO/TC 229, CEN/TC/352, ASTM/E56, and IEC/TC 113) and regulatory relevant guidelines (incl. OECD Test Guidelines and Guidance Documents).
By now, this has led to the development of 215 standardisation and harmonisation documents, but many more still need to be developed; Dr Friedrichs listed 38 gaps in the standardisation and harmonisation landscape that have already been identified by TEMAS Solutions, partner of the MACRAMÉ Project (cf. Towards harmonisation of testing of nanomaterials for EU regulatory requirements on chemical safety).
20230613_MACRAME_EuroNanoForum2023_SFriedrichs.pdf
Shared Responsibilities & collaborative R&I Approaches – Ensuring safe & sustainable Products & Processes throughout complex Value-Chains
MACRAMÉ’s Central Objective is to:
• detect, characterise and quantify AdMas during handling and processing along the product life-cycle,
• assess potential impacts on (human) health and the environment in intended or unintended exposure situations (i.e. ‘Exposure Points’) in the product value-chain,
• advance the wide-spread applicability of the developed test and characterisation methods, by demonstrating their effectiveness and efficiency in the context of existing, market-relevant industrial AdMas containing products, and
• prepare and initiate standardisation, harmonisation and technological & regulatory validation of test- and characterisation-methods.
The MACRAMÉ Project is fully aligned with the EU ambitions to secure the safety and sustainability of new chemicals, materials, products and processes in order to strive for zero pollution and toxic-free environments, as addressed in the EU’s Chemical Strategy for Sustainability (2020), and in the European Green Deal (2021); in doing so, the Project concentrates on methodologies that are applicable to nanomaterials, and widens them to ‘Advanced Materials’ (AdMas) ⎼ a material category that includes but surpasses that of ‘nanomaterials’ (EU, ‘Definition of a Nanomaterial’) - in commercialised products and that are aligned with the future-oriented innovation, safety and sustainability considerations of the OECD (OECD (2020)), the EU (EU (2022)), and several of its Member States (e.g. Germany (2021)). This will be achieved through development and demonstration of novel methodologies, and by advancing their harmonisation & standardisation on three MACRAMÉ Material Families of inhalable carbon-based AdMas of various morphologies and dimensions (Tiwari et al. (2012)), beyond spherical particles: (a) graphene-related material (GRM), (b) carbon nanofibres (CNFs), e.g., carbon nanotubes (CNTs), and (c) Poly Lactic-co-Glycolic Acid (nano)particles (PLGA). The focus on carbon-based AdMas addresses unsolved detection and characterisation issues, especially in complex media. In doing so, MACRAMÉ builds on >15 years of research and innovation (R&I) and knowledge pooling in nanosafety, formed through numerous European and international collaborations. MACRAMÉ will add value to the results of collaborations, such as the Malta-Initiative, and the Graphene Flagship Validation Service and Standardisation Committee, to proactively support EU industries in becoming world-leaders in clean technologies and products and achieving the Green Deal’s ambitious timeline.
This will be achieved by defining the R&I Strategy through life-cycle assessment for five market-relevant industrial MACRAMÉ Use-Cases. These define the selection of the MACRAMÉ R&I Activities and development of MACRAMÉ Methods, and the benchmarks chosen for monitoring the progress R&I.
US-Launch_NanoFabNet-Hub
This event saw the launch of a strong international hub for sustainable high-tech innovation, whose structure, business model, detailed strategies and action plans are designed, agreed and carried by its international stakeholders, in order to yield a self-sustaining collaboration platform: the NanoFabNet Hub.
The Hub aims to provide a one-stop-shop for all matters and concerns pertaining to sustainable high-tech innovation and its successful incorporation into the complex, large-scale high-value industries by bringing together governmental and academic laboratories with large industries and SMEs.
NanoFabNet Launch Event
Presentation by the NanoFabNet Team to launch the NanoFabNet Hub (6th July 2022, Braga, Portugal)
NanoFabNet Hub – Objectives:
• Create a strong international hub for sustainable high-tech innovation, whose structure, business model, detailed strategies and action plans are designed, agreed and carried by its international stakeholders, in order to yield a self-sustaining collaboration platform: the NanoFabNet Hub.
• A registered Secretariat at the Hub’s centre will provide an accountable, economically sustainable executive.
• The Hub aims to provide a one-stop-shop for all matters and concerns pertaining to sustainable high-tech innovation and its successful incorporation into the complex, large-scale high-value industries by bringing together governmental and academic laboratories with large industries and SMEs.
The NanoFabNet Hub is a network of micro- & nanotechnology as well as sustainability professionals, coming together to build a strong, sustainable high-tech sector ...
… by focussing on the following activity fields:
• Micro- & Nanotechnology Research & Innovation, Fabrication & Manufacturing
• Sustainability (incl. Life-Cycle Assessment & Ethics)
• Safety (incl. regulatory Risk Assessment)
• Technology Validation & Inter-Laboratory Studies
• Harmonisation & Standardisation & Pre-Standardisation
• Laboratory Infrastructures
• Education & Skills (incl. Training- & Career Opportunities)
• International Cooperations & Collaborations (incl. Collaborations Market Place)
NanoFabNet Products & Services:
• Database of >250 relevant Standardisation & Harmonisation Documents (regularly updated)
• Database of relevant documents on safety-, ethics- and governance-considerations in the high-tech sector (curated & regularly updated)
• International Market-Place for R&I Collaboration and B2B-Services
• Match-Making of Sustainability Opportunities in High-Tech
• Information about and Contribution to (Pre)Standardisation & regulatory Harmonisation Processes
• Training, Career-Development & Jobs-Market
• (Speciality) Technology Validation Services
• Organisation of Proficiency Testing
Concepts of Sustainable Nanofabrication
The document discusses the NanoFabNet Hub, which aims to create a sustainable international collaboration platform for nanofabrication. The Hub will provide a registered secretariat and be a one-stop-shop for matters related to sustainable nanofabrication. It will bring together governmental laboratories, academics, large industries, and SMEs. The document also summarizes workshops that were held to discuss concepts of sustainable nanofabrication and mapping areas of research at the intersection of nanotechnology and sustainability.
Nanotechnology & the (Re-)Insurance Industry
Based on an in-depth analysis conducted for the Gov4Nano Project, Dr Steffi Friedrichs delivered a seminar entitled 'Nanotechnology & the Insurance Industry' as part of the Environmental Health Sciences Seminar Series (Fall 2020) at the University of South Carolina.
Presentation by Dr Steffi Friedrichs at the 4th Gov4Nano Consortium Meeting (...
Nanotechnology and the Insurance Industry: presentation by Dr Steffi Friedrichs (AcumenIST) to the 4th Gov4Nano Consortium Meeting.
Presentation by Dr Steffi Friedrichs at the 2020 UNIDIR Innovation Dialogues
This presentation aimed to provide real-life examples of the possible dual-use of nanobiotechnology application, focusing on the interface between inorganic nanotechnology and living organisms.
'The Regulatory Landscape of Genome Editing' - Panel Discussion during the
During the 8th Plant Genomics and Gene Editing Congress: Europe, held on the 4th and 5th March 2020 in Rotterdam, a panel of experts explored and discussed 'The Regulatory Landscape' of Genome Editing:
Presentation by Dr Steffi Friedrichs, AcumenIST, NanoEarth, Virginia Tech, 8....
Title: The ‘Rise and Fall’ of Technologies (on the Example of Biotechnology and Nanotechnology)
Biotechnology has often been referred to as the bigger sister of nanotechnology. Indeed, the difference between the two technologies is often reduced to a mere two-decade time warp between the technologies’ hype cycles, and both technology analysists, policy-makers and pressure groups continue to entertain each other with numerous stories about the exchangeability of the two technology names in meeting agendas, expert panel discussions, public debates and policy documents.
This talk by Steffi Friedrichs, however, highlights the difference between the two technologies and outline the potential pitfalls (for both the public and the private sector) in reducing the expected trajectory of any technology’s development to a mere copy of a previous experience.
Steffi discusses the evidence recently published in two in-depth reports on the development of biotechnology and nanotechnology and their resulting impacts:
1. The Report on statistics and indicators of biotechnology and nanotechnology brings together the latest available patenting and bibliometric activity data on biotechnology, nanotechnology and related emerging and converging technologies. In order to achieve a comparison between the two technology fields, the selected indicators and measurement methodology for these multidisciplinary and partially overlapping technologies were re-confirmed and stress-tested with a view to establishing uniquely accurate and relevant datasets.
2. The Trend-analysis of science, technology and innovation policies for BNCTs studied the policies pertaining to nanotechnology and biotechnology over the past three decades and analysed them with regard to their directionality (i.e. the characteristics differentiating “technology-push” from “application-pull” policies) and their generality (i.e. the antonym of a technology-specificity that limits a policy to be applicable to a specific technology field only).
(NOTE: this PDF of the original presentation has been annotated for sharing.)
Presentation by Dr Steffi Friedrichs, AcumenIST, Human Germline Genome Editin...
Title: The Debate on Human Germline Genome Editing in the Context of Evidence and Opinion
Advancements in the life sciences recently appear to have been dominated by the topic of genome editing. Owing to the breakthrough discovery of the CRISPR/Cas9 methodology (i.e. a system, based on an RNA-guided nuclease, that was shown to cleave target genome sequences with a high specificity) in 2012, genome editing became an easily accessible and applicable tool in genome modification laboratories around the world – ranging from agricultural research on plants and animals to environmental pest controls and to advanced medicine. Within this vast field of potential applications, it is the niche of human germline genome editing that is most hotly debated in both scientific, regulatory and public fora.
This presentation aims to provide an overview of the debates that have hitherto been conducted on the topic of “human germline genome editing”, and to highlight the opinions aired by the various stakeholder groups (including the research community, various groups of medical practitioners, patient groups, the general public, policy makers, ethicists, and religious organisations); within these the expert research and medical practitioner communities occupy a pivotal position that merits a detailed analysis and discussion of arguments.
As with any other rapidly advancing and hotly discussed technological advancement, the presentation is to be understood as a mere snapshot of the current status of the debate on human germline genome editing. It will furthermore outline some societal and political contexts, in which the discussions need to be regarded, and draw some historical analogies, in order to ultimately inform the symposium and the winter school.
More from Steffi Friedrichs (13)
MACRAMÉ Contribution to the 'Standardisation Workshop & Panel Discussion' at ...
MACRAMÉ Contribution to the 'Standardisation Workshop & Panel Discussion' at ...
20230613_MACRAME_EuroNanoForum2023_SFriedrichs.pdf
20230613_MACRAME_EuroNanoForum2023_SFriedrichs.pdf
Presentation by Dr Steffi Friedrichs at the 4th Gov4Nano Consortium Meeting (...
Presentation by Dr Steffi Friedrichs at the 4th Gov4Nano Consortium Meeting (...
Presentation by Dr Steffi Friedrichs at the 2020 UNIDIR Innovation Dialogues
Presentation by Dr Steffi Friedrichs at the 2020 UNIDIR Innovation Dialogues
'The Regulatory Landscape of Genome Editing' - Panel Discussion during the
'The Regulatory Landscape of Genome Editing' - Panel Discussion during the
Presentation by Dr Steffi Friedrichs, AcumenIST, NanoEarth, Virginia Tech, 8....
Presentation by Dr Steffi Friedrichs, AcumenIST, NanoEarth, Virginia Tech, 8....
Presentation by Dr Steffi Friedrichs, AcumenIST, Human Germline Genome Editin...
Presentation by Dr Steffi Friedrichs, AcumenIST, Human Germline Genome Editin...
Recently uploaded
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
Reaching the age of Adolescence- Class 8
This is a presentation on understanding the age of adolescence.
Firoozeh Kashani-Sabet - An Esteemed Professor
Dr. Firoozeh Kashani-Sabet is an innovator in Middle Eastern Studies and approaches her work, particularly focused on Iran, with a depth and commitment that has resulted in multiple book publications. She is notable for her work with the University of Pennsylvania, where she serves as the Walter H. Annenberg Professor of History.
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...ABHISHEK SONI NIMT INSTITUTE OF MEDICAL AND PARAMEDCIAL SCIENCES , GOVT PG COLLEGE NOIDA
Microbial interaction
Microorganisms interacts with each other and can be physically associated with another organisms in a variety of ways.
One organism can be located on the surface of another organism as an ectobiont or located within another organism as endobiont.
Microbial interaction may be positive such as mutualism, proto-cooperation, commensalism or may be negative such as parasitism, predation or competition
Types of microbial interaction
Positive interaction: mutualism, proto-cooperation, commensalism
Negative interaction: Ammensalism (antagonism), parasitism, predation, competition
I. Mutualism:
It is defined as the relationship in which each organism in interaction gets benefits from association. It is an obligatory relationship in which mutualist and host are metabolically dependent on each other.
Mutualistic relationship is very specific where one member of association cannot be replaced by another species.
Mutualism require close physical contact between interacting organisms.
Relationship of mutualism allows organisms to exist in habitat that could not occupied by either species alone.
Mutualistic relationship between organisms allows them to act as a single organism.
Examples of mutualism:
i. Lichens:
Lichens are excellent example of mutualism.
They are the association of specific fungi and certain genus of algae. In lichen, fungal partner is called mycobiont and algal partner is called
II. Syntrophism:
It is an association in which the growth of one organism either depends on or improved by the substrate provided by another organism.
In syntrophism both organism in association gets benefits.
Compound A
Utilized by population 1
Compound B
Utilized by population 2
Compound C
utilized by both Population 1+2
Products
In this theoretical example of syntrophism, population 1 is able to utilize and metabolize compound A, forming compound B but cannot metabolize beyond compound B without co-operation of population 2. Population 2is unable to utilize compound A but it can metabolize compound B forming compound C. Then both population 1 and 2 are able to carry out metabolic reaction which leads to formation of end product that neither population could produce alone.
Examples of syntrophism:
i. Methanogenic ecosystem in sludge digester
Methane produced by methanogenic bacteria depends upon interspecies hydrogen transfer by other fermentative bacteria.
Anaerobic fermentative bacteria generate CO2 and H2 utilizing carbohydrates which is then utilized by methanogenic bacteria (Methanobacter) to produce methane.
ii. Lactobacillus arobinosus and Enterococcus faecalis:
In the minimal media, Lactobacillus arobinosus and Enterococcus faecalis are able to grow together but not alone.
The synergistic relationship between E. faecalis and L. arobinosus occurs in which E. faecalis require folic acid
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
Ahota Beel, nestled in Sootea Biswanath Assam , is celebrated for its extraordinary diversity of bird species. This wetland sanctuary supports a myriad of avian residents and migrants alike. Visitors can admire the elegant flights of migratory species such as the Northern Pintail and Eurasian Wigeon, alongside resident birds including the Asian Openbill and Pheasant-tailed Jacana. With its tranquil scenery and varied habitats, Ahota Beel offers a perfect haven for birdwatchers to appreciate and study the vibrant birdlife that thrives in this natural refuge.
Mechanics:- Simple and Compound Pendulum
a compound pendulum is a physical system with a more complex structure than a simple pendulum, incorporating its mass distribution and dimensions into its oscillatory motion around a fixed axis. Understanding its dynamics involves principles of rotational mechanics and the interplay between gravitational potential energy and kinetic energy. Compound pendulums are used in various scientific and engineering applications, such as seismology for measuring earthquakes, in clocks to maintain accurate timekeeping, and in mechanical systems to study oscillatory motion dynamics.
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Music and Medieval History
Explainable Deepfake Image/Video Detection
Presentation of our paper, "Towards Quantitative Evaluation of Explainable AI Methods for Deepfake Detection", by K. Tsigos, E. Apostolidis, S. Baxevanakis, S. Papadopoulos, V. Mezaris. Presented at the ACM Int. Workshop on Multimedia AI against Disinformation (MAD’24) of the ACM Int. Conf. on Multimedia Retrieval (ICMR’24), Thailand, June 2024. https://doi.org/10.1145/3643491.3660292 https://arxiv.org/abs/2404.18649
Software available at https://github.com/IDT-ITI/XAI-Deepfakes
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Centrifugation is a powerful technique used in laboratories to separate components of a heterogeneous mixture based on their density. This process utilizes centrifugal force to rapidly spin samples, causing denser particles to migrate outward more quickly than lighter ones. As a result, distinct layers form within the sample tube, allowing for easy isolation and purification of target substances.
Signatures of wave erosion in Titan’s coasts
The shorelines of Titan’s hydrocarbon seas trace flooded erosional landforms such as river valleys; however, it isunclear whether coastal erosion has subsequently altered these shorelines. Spacecraft observations and theo-retical models suggest that wind may cause waves to form on Titan’s seas, potentially driving coastal erosion,but the observational evidence of waves is indirect, and the processes affecting shoreline evolution on Titanremain unknown. No widely accepted framework exists for using shoreline morphology to quantitatively dis-cern coastal erosion mechanisms, even on Earth, where the dominant mechanisms are known. We combinelandscape evolution models with measurements of shoreline shape on Earth to characterize how differentcoastal erosion mechanisms affect shoreline morphology. Applying this framework to Titan, we find that theshorelines of Titan’s seas are most consistent with flooded landscapes that subsequently have been eroded bywaves, rather than a uniform erosional process or no coastal erosion, particularly if wave growth saturates atfetch lengths of tens of kilometers.
Methods of grain storage Structures in India.pdf
•Post-harvestlossesaccountforabout10%oftotalfoodgrainsduetounscientificstorage,insects,rodents,micro-organismsetc.,
•Totalfoodgrainproductioninindiais311milliontonnesandstorageis145mt.InIndia,annualstoragelosseshavebeenestimated14mtworthofRs.7,000croreinwhichinsectsaloneaccountfornearlyRs.1,300crores.
•InIndiaoutofthetotalproduction,about30%ismarketablesurplus
•Remaining70%isretainedandstoredbyfarmersforconsumption,seed,feed.Hence,growerneedstoragefacilitytoholdaportionofproducetosellwhenthemarketingpriceisfavourable
•TradersandCo-operativesatmarketcentresneedstoragestructurestoholdgrainswhenthetransportfacilityisinadequate
Synopsis presentation VDR gene polymorphism and anemia (2).pptx
I am the PhD scholar of FND department, Assam down town University
Recently uploaded (20)
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Juaristi, Jon. - El canon espanol. El legado de la cultura española a la civi...
Juaristi, Jon. - El canon espanol. El legado de la cultura española a la civi...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Synopsis presentation VDR gene polymorphism and anemia (2).pptx
Synopsis presentation VDR gene polymorphism and anemia (2).pptx
Nutaceuticsls herbal drug technology CVS, cancer.pptx
Nutaceuticsls herbal drug technology CVS, cancer.pptx
INSIGHT Partner Profile: Tampere University
- 1. Angela Serra Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE) I am a Lecturer in Health Data Science at Tampere University, specialized in applying data science and machine learning to bioinformatics and cheminformatics. My research is focused on developing innovative data integration methodologies for chemical safety assessment and drug discovery. In INSIGHT, I act as a WP2 leader where we aim to retrieve, implement and FAIRIFy models for health, environmental, economic and social impact of chemicals. It is my honor to be a part of this team and contribute to great science. Lecturer
- 2. Laura Saarimäki Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE) I am a Postdoctoral researcher at FHAIVE, with expertise in mechanistic toxicology, particularly in the form of Adverse Outcome Pathways (AOPs), toxicogenomics, and their integration. In INSIGHT, my main role is leading Task 4.2 within WP 4, focusing on the development of integrated mechanistic models of impact. These models aim to comprehensively address impacts of chemicals on human health, the environment, and socio-economic aspects across their whole life cycle. The interdisciplinary nature of this task, and in fact the whole project, offers stimulating opportunities to learn beyond our specific fields. Postdoctoral Researcher
- 3. Marcella T. Maia Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE) With a Biotechnology background, I have developed expertise in Materials Science, Data Analysis and Toxicogenomic. Currently, I am working as a research assistant in FHAIVE. My research focuses on engineered nanomaterials (ENM) safety assessment to comprehend their adverse health effects within the Adverse Outcome Pathway framework as well as exploring associations between ENM impact and physicochemical characteristics. In INSIGHT, I will contribute to WP3, retrieving and analyzing public data to incorporate into a multilayer framework. Research Assistant
- 4. Ratul Bhowmik Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE) Currently, I am working as a PhD student in FHAIVE. I have expertise in Cheminformatics, computational drug discovery, and basic system biology approaches. My role in INSIGHT will be focused on developing novel computational methods involving knowledge graphs and mechanistic QSAR approaches to generate interpretable models that will be further used to evaluate chemicals that have a significant effect on health, environment, and socio-economic factors. PhD Researcher